Our Story

Founded by Doctors. Focused on Patients.

Imbria’s unique approach to cardiovascular therapeutics targets the heart’s energy metabolism to improve cardiac efficiency, thereby helping patients with serious cardiovascular disorders feel and function better.

Our lead candidate, ninerafaxstat, is a potential first-in-class therapy designed to improve heart function safely and effectively in diseases characterized by energetic impairment, including non-obstructive hypertrophic cardiomyopathy (nHCM) and heart failure with preserved ejection fraction (HFpEF). The U.S. Food and Drug Administration has granted Orphan Drug Designation to ninerafaxstat for the treatment of symptomatic nHCM.

Guided by science. Driven by patient need.

By enhancing or restoring the cell’s ability to produce and use energy, we aim to address a fundamental driver of cardiovascular disease.